Wall Street Analyst Initiated Yield10 Bioscience Inc. [YTEN]. What else is Wall St. saying

Yield10 Bioscience Inc. [NASDAQ: YTEN] price surged by 49.99 percent to reach at $1.05. The company report on January 11, 2023 that Yield10 Bioscience and Mitsubishi Corporation Sign MOU to Evaluate the Establishment of a Partnership to Supply, Offtake and Market Camelina as a Feedstock Oil for Biofuel.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Under the MOU, the companies plan to jointly undertake a feasibility study for the supply and offtake of Camelina oil from Camelina grain grown under contract using Yield10’s proprietary Camelina seed genetics to supply oil for the sustainable aviation fuel market. In addition, the companies also plan to jointly study the development and future offtake and marketing of PHA bioplastic produced in Camelina by Yield10 as an added value co-product with oil for biofuels. The MOU is non-binding and expires at the end of 2023.

A sum of 12064064 shares traded at recent session while its average daily volume was at 32.31K shares. Yield10 Bioscience Inc. shares reached a high of $3.45 and dropped to a low of $2.69 until finishing in the latest session at $3.15.

The one-year YTEN stock forecast points to a potential upside of 74.29. The average equity rating for YTEN stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Yield10 Bioscience Inc. [YTEN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for YTEN shares is $12.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on YTEN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Yield10 Bioscience Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 10, 2020. The new note on the price target was released on August 27, 2020, representing the official price target for Yield10 Bioscience Inc. stock.

The Average True Range (ATR) for Yield10 Bioscience Inc. is set at 0.29, with the Price to Sales ratio for YTEN stock in the period of the last 12 months amounting to 31.56. The Price to Book ratio for the last quarter was 2.14, with the Price to Cash per share for the same quarter was set at 1.48.

YTEN Stock Performance Analysis:

Yield10 Bioscience Inc. [YTEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 59.09. With this latest performance, YTEN shares gained by 89.76% in over the last four-week period, additionally plugging by 20.69% over the last 6 months – not to mention a drop of -20.05% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for YTEN stock in for the last two-week period is set at 74.57, with the RSI for the last a single of trading hit 82.60, and the three-weeks RSI is set at 68.12 for Yield10 Bioscience Inc. [YTEN]. The present Moving Average for the last 50 days of trading for this stock 2.18, while it was recorded at 2.18 for the last single week of trading, and 2.76 for the last 200 days.

Insight into Yield10 Bioscience Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Yield10 Bioscience Inc. [YTEN] shares currently have an operating margin of -1904.23 and a Gross Margin at +5.86. Yield10 Bioscience Inc.’s Net Margin is presently recorded at -1796.58.

Return on Equity for this stock declined to -86.32, with Return on Assets sitting at -63.15.

Yield10 Bioscience Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.30 and a Current Ratio set at 4.30.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for YTEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Yield10 Bioscience Inc. go to 0.00%.

Yield10 Bioscience Inc. [YTEN] Insider Position Details

There are presently around $1 million, or 8.40% of YTEN stock, in the hands of institutional investors. The top three institutional holders of YTEN stocks are: CANNELL & CO. with ownership of 161,238, which is approximately -0.062% of the company’s market cap and around 1.90% of the total institutional ownership; VANGUARD GROUP INC, holding 103,371 shares of the stock with an approximate value of $0.33 million in YTEN stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.11 million in YTEN stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Yield10 Bioscience Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 3 institutional holders increased their position in Yield10 Bioscience Inc. [NASDAQ:YTEN] by around 16,952 shares. Additionally, 7 investors decreased positions by around 67,353 shares, while 7 investors held positions by with 312,242 shares. The mentioned changes placed institutional holdings at 396,547 shares, according to the latest SEC report filing. YTEN stock had 2 new institutional investments in for a total of 16,950 shares, while 3 institutional investors sold positions of 21,634 shares during the same period.


Please enter your comment!
Please enter your name here